M&T Bank
CASC

M&T Bank’s Cascadian Therapeutics, Inc. CASC Stock Holding History

M&T Bank’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,707
Closed -$20K – 2311
2014
Q3 		$20K Buy
1,707
+1,568
+1,128% +$24K ﹤0.01% 2160
2014
Q2 		$3K Hold
139
– – ﹤0.01% 1033
2014
Q1 		$2K Hold
139
– – ﹤0.01% 1161
2013
Q4 		$1K Hold
139
– – ﹤0.01% 1079
2013
Q3 		$2K Hold
139
– – ﹤0.01% 992
2013
Q2 		$1K Buy
+139
New +$1.78K ﹤0.01% 1038

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

M&T Bank's CASC Position: Q4 2014 in Review

M&T Bank sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2014, closing a stake of 1,707 shares — an estimated $20K sold.

M&T Bank first reported a position in CASC in Q2 2013 and held it in 6 quarters. The position peaked at $20K in Q3 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q4 2014.

  • M&T Bank reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • M&T Bank sold 1,707 Cascadian Therapeutics, Inc. shares in Q4 2014, an estimated $20K.
  • M&T Bank first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
  • M&T Bank's Cascadian Therapeutics, Inc. position peaked at $20K in Q3 2014.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2014.

Based on M&T Bank's 13F filing for Q4 2014, filed 12 Feb 2015.